GPC3-Targeted PET Imaging with 18F-X12 in Liver Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This diagnostic study evaluates the safety and effectiveness of the radiotracer 18F-X12 for PET/CT imaging in patients with hepatocellular carcinoma (HCC). It aims to determine how well 18F-X12 PET/CT identifies HCC presence, stage tumors, and detects recurrence. Participants may be adults with suspected or confirmed HCC who have not yet received systemic therapy, or those who have undergone prior treatment and are undergoing clinical staging or restaging. The study is conducted at Peking University First Hospital under a sponsor-led protocol. Safety and diagnostic performance data will be collected to support potential clinical use of 18F-X12 in HCC management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥ 18 years old.
* Patients fully understand the trial requirements, participate in the study voluntarily, and provide written informed consent.
* Meet either of the following two conditions:
* Patients with highly suspected hepatocellular carcinoma (HCC) (hepatic space-occupying lesion of undetermined nature on imaging examination) or pathologically confirmed HCC, with no prior systemic therapy (including immunotherapy, chemoradiotherapy, targeted therapy, etc.) or suspected tumor recurrence after previous treatment, and able to independently cooperate with relevant examinations.
* Patients with clinically diagnosed HCC who have received 18F-FDG positron emission tomography/computed tomography (PET/CT) for clinical staging or post-treatment restaging, and able to independently cooperate with relevant examinations.

Exclusion Criteria:

* Patients with severe non-malignant diseases that may interfere with study objectives, or impair subject safety and study compliance, including but not limited to psychiatric disorders, infectious diseases, autoimmune diseases, and metabolic diseases.
* Pregnant or lactating females.
* Subjects who are unable to understand the examination procedure or cannot cooperate with trial-related examinations and operations.

Where it's running

• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Meng Liu — Peking University First Hospital
• Study coordinator: Meixi Chen
• Email: 2511210177@bjmu.edu.cn
• Phone: +86 010-83575252

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• AI-guided treatment choices for advanced liver cancer

  Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.

  Recruiting at 5 sites Universitaire Ziekenhuizen KU Leuven · Anderlecht and 4 other locations · NCT07863258

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Biomarker testing to predict treatment response and recurrence in liver cancer

  This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07840092

• MRI plus diffusion and CEST imaging to map liver cancer and its immune environment

  This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07838415

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.